ATE359828T1 - Abgabesystem für antineoplastische arzneistoffe auf basis dendritischer polymere - Google Patents

Abgabesystem für antineoplastische arzneistoffe auf basis dendritischer polymere

Info

Publication number
ATE359828T1
ATE359828T1 AT01993291T AT01993291T ATE359828T1 AT E359828 T1 ATE359828 T1 AT E359828T1 AT 01993291 T AT01993291 T AT 01993291T AT 01993291 T AT01993291 T AT 01993291T AT E359828 T1 ATE359828 T1 AT E359828T1
Authority
AT
Austria
Prior art keywords
dendritic polymer
antineoplastic
functional groups
antineoplastic agent
delivery system
Prior art date
Application number
AT01993291T
Other languages
English (en)
Inventor
Navid Malik
Ruth Duncan
Donald A Tomalia
Roseita Esfand
Original Assignee
Dendritic Nanotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dendritic Nanotechnologies Inc filed Critical Dendritic Nanotechnologies Inc
Application granted granted Critical
Publication of ATE359828T1 publication Critical patent/ATE359828T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
AT01993291T 2001-10-29 2001-10-29 Abgabesystem für antineoplastische arzneistoffe auf basis dendritischer polymere ATE359828T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2001/048568 WO2003037383A1 (en) 2001-10-29 2001-10-29 An antineoplastic- dendritic polymer drug delivery system

Publications (1)

Publication Number Publication Date
ATE359828T1 true ATE359828T1 (de) 2007-05-15

Family

ID=21743124

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01993291T ATE359828T1 (de) 2001-10-29 2001-10-29 Abgabesystem für antineoplastische arzneistoffe auf basis dendritischer polymere

Country Status (6)

Country Link
EP (1) EP1439859B1 (de)
JP (1) JP2005507933A (de)
CN (1) CN1558777A (de)
AT (1) ATE359828T1 (de)
DE (1) DE60128011T2 (de)
WO (1) WO2003037383A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60131177T2 (de) 2000-09-06 2008-08-07 AP Pharma, Inc., Redwood Abbaubare polyacetal-polymere
US7754500B2 (en) * 2003-11-21 2010-07-13 Anp Technologies, Inc. Asymmetrically branched polymer conjugates and microarray assays
DE102004039875A1 (de) 2004-08-17 2006-03-09 Universität Dortmund Nanotransportsystem mit dendritischer Architektur
CN1332716C (zh) * 2005-05-25 2007-08-22 北京市海格里斯科技有限公司 一种高分子抗肿瘤顺铂药物及其制备方法
JP5264492B2 (ja) 2005-10-25 2013-08-14 エボニック デグサ ゲーエムベーハー 超分岐ポリマーを含有する調製物
DE102007026397A1 (de) 2007-06-06 2008-12-11 Fu Berlin Nanokomplexe mit dendritischer Struktur zur Einlagerung und/oder zum Transport von monovalenten Metallionen
FR2922452B1 (fr) * 2007-10-19 2010-01-22 Coatex Sas Formulations de composes organoplatiniques en presence de polymeres associatifs, produits obtenus et leurs utilisations
JP5302340B2 (ja) * 2008-01-30 2013-10-02 カンザス大学 リンパ管内化学療法薬物担体
DE102008042923A1 (de) 2008-10-17 2010-04-22 Evonik Goldschmidt Gmbh Präparate zur gesteuerten Freisetzung von Wirkstoffen
WO2011053605A1 (en) * 2009-10-26 2011-05-05 Dendritic Nanotechnologies, Inc. Peham dendrimers for use in agriculture
JPWO2015170573A1 (ja) * 2014-05-08 2017-04-20 公立大学法人大阪府立大学 リンパ節イメージング剤
GR1009107B (el) * 2016-07-11 2017-09-08 Εκεφε Δημοκριτος Καινοτομα λειτουργικα συστηματα μεταφορας αμινοκινολινων και παραγωγων τους βασισμενα σε δενδριτικα πολυμερη με ικανοτητα στοχευσης μιτοχονδριων
CN111116928B (zh) * 2019-10-28 2021-11-12 西北工业大学 一种以双药物分子为基元的超分子超支化聚合物及制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5938934A (en) * 1998-01-13 1999-08-17 Dow Corning Corporation Dendrimer-based nanoscopic sponges and metal composites
ITFO990015A1 (it) * 1999-07-23 2001-01-23 Verdini Antonio "dendrimeri polipeptidici quali trasportatori unimolecolari di farmaci e sostanze biologicamente attive".
EP1118333A1 (de) * 2000-01-18 2001-07-25 Eurand International S.P.A. Zusammensetzungen mit erhöhter oraler Bioverfügbarkeit

Also Published As

Publication number Publication date
EP1439859B1 (de) 2007-04-18
DE60128011T2 (de) 2007-12-27
WO2003037383A1 (en) 2003-05-08
JP2005507933A (ja) 2005-03-24
CN1558777A (zh) 2004-12-29
DE60128011D1 (de) 2007-05-31
EP1439859A1 (de) 2004-07-28

Similar Documents

Publication Publication Date Title
DE60128011D1 (de) Abgabesystem für antineoplastische arzneistoffe auf basis dendritischer polymere
Li et al. Synchronously manipulating absorption and extinction coefficient of semiconducting polymers via precise dual‐acceptor engineering for nir‐ii excited photothermal theranostics
RU2335512C2 (ru) Координационный комплекс диаминоциклогексана платины (ii) с блоксополимером, содержащим сегмент поли(карбоновой кислоты), и включающий его противораковый агент
Zan et al. Dual pH-triggered multistage drug delivery systems based on host–guest interaction-associated polymeric nanogels
ATE306251T1 (de) Verwendung eines biologisch abbaubaren polymers
Jun et al. Selective tumor targeting by enhanced permeability and retention effect. Synthesis and antitumor activity of polyphosphazene–platinum (II) conjugates
WO1995030423A3 (en) Cancer treatment and metastasis prevention
Qian et al. Drug-polymer hybrid macromolecular engineering: Degradable PEG integrated by platinum (IV) for cancer therapy
Hsieh et al. Tumor site-specific PEG detachment and active tumor homing of therapeutic PEGylated chitosan/folate-decorated polydopamine nanoparticles to augment antitumor efficacy of photothermal/chemo combination therapy
Gianasi et al. HPMA copolymers platinates containing dicarboxylato ligands. Preparation, characterisation and in vitro and in vivo evaluation
US20120197060A1 (en) Radiation enhanced macromolecular delivery of therapeutic agents for chemotherapy technology
ATE238813T1 (de) Wirkstoffformulierungen mit verzögerter freisetzung
IL144087A0 (en) Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same
CN102580113B (zh) 一种顺铂超分子胶束前药的制备方法
Wang et al. Tailor-made gemcitabine prodrug nanoparticles from well-defined drug–polymer amphiphiles prepared by controlled living radical polymerization for cancer chemotherapy
Zou et al. Effectiveness of water soluble poly (L-glutamic acid)-camptothecin conjugate against resistant human lung cancer xenografted in nude mice
Zhang et al. Design and development of multifunctional polyphosphoester-based nanoparticles for ultrahigh paclitaxel dual loading
Dong et al. Nucleobase-crosslinked poly (2-oxazoline) nanoparticles as paclitaxel carriers with enhanced stability and ultra-high drug loading capacity for breast cancer therapy
Cheng et al. Homologous cancerous cell membrane modulated multifunctional nanoshuttles: Targeting specificity and improved tumor theranostics
JP4992089B2 (ja) ジアミノシクロヘキサン白金（ｉｉ）とブロック共重合体との配位化合物及びそれを含有する抗がん剤
Migasová et al. Histidine-modified UiO-66 (Zr) nanoparticles as an effective pH-responsive carrier for 5-fluorouracil drug delivery system: A possible pathway to more effective brain cancer treatments
CN109432051B (zh) 一种具有抗卵巢癌活性的靶向纳米粒及制备和应用
Ruan et al. Non-invasive imaging of breast cancer using RGDyK functionalized fluorescent carbonaceous nanospheres
Hoskins et al. In vitro and in vivo anticancer activity of a novel nano-sized formulation based on self-assembling polymers against pancreatic cancer
US20140072604A1 (en) Block Copolymer For Intraperitoneal Administration Containing Anti-Cancer Agent, Micelle Preparation Thereof, And Cancer Therapeutic Agent Comprising The Micelle Preparation As Active Ingredient

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties